Written by Administrator | Aug 08, 2011

 BioCentury TV: Pfizer Biosimilars Business Unit General Manager Diem Nguyen interviewed on the Company's biosimilars strategy

Written by Amy Ritter | Jul 08, 2011

Pfizer’s Biosimilar Strategy

Revenue from the sale of biosimilars is expected to grow from $311 million in
2010 to $2–$2.5 billion in 2015, according to IMS Health in their report, The Global Use of
Medicines: Outlook Through 2015 released in May 2011,. With all that revenue to be captured,
it is no surprise that large pharmaceutical companies are diversifying their portfolios to
accommodate this product area. When Pfizer acquired Wyeth in 2009, part of the value of that
deal for Pfizer came from the acquisition of Wyeth’s development and manufacturing
capabilities for biologics and vaccines, capabilities that put the company in position to enter the
growing biosimilars market.

Written by Vikas Dandekar | Jun 30, 2011

Armed With A Range Of Insulins, Pfizer Is Weeks Away From Its First Biosimilars Rollout In India - BIO 2011 Conference

WASHINGTON - Pfizer Inc. is all set to kick-off its journey into the world of biosimilars
as it gives finishing touches to the launch of a range of insulins in India. The company is
counting on a set of value propositions, high quality and competitive pricing to emerge
as a "natural leader" in the Indian market.